China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported a slight increase in net profit to approximately 684 million RMB for the nine months ending September 2024, despite a decline in revenue. The company’s cash position improved significantly by the end of the period, reflecting stronger cash management. Investors are advised to consider these figures cautiously as they are unaudited and may require adjustments.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
